Omeros Corp Files 8-K Report
Ticker: OMER · Form: 8-K · Filed: Jan 16, 2025 · CIK: 1285819
| Field | Detail |
|---|---|
| Company | Omeros Corp (OMER) |
| Form Type | 8-K |
| Filed Date | Jan 16, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC filing, pharmaceuticals
Related Tickers: OMER
TL;DR
OMER filed an 8-K, likely routine docs. No major news yet.
AI Summary
On January 16, 2025, Omeros Corporation filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text. The company is based in Seattle, Washington, and operates in the pharmaceutical preparations industry.
Why It Matters
This 8-K filing indicates that Omeros Corporation is providing updates or submitting required financial documentation to the SEC, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report, indicating routine corporate disclosures rather than a specific event with immediate high risk.
Key Numbers
- 001-34475 — SEC File Number (Identifies the company's filing with the SEC.)
- 91-1663741 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- OMEROS CORP (company) — Registrant
- January 16, 2025 (date) — Date of earliest event reported
- Seattle, WA (location) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported by Omeros Corporation in this 8-K filing?
The provided text for the 8-K filing does not specify the details of the 'Other Events' beyond listing it as an item information category.
What is the primary purpose of this 8-K filing for Omeros Corporation?
The filing is a Current Report on Form 8-K, indicating it's to report information deemed material to stockholders that is not required to be reported in a periodic report, and it specifically lists 'Other Events' and 'Financial Statements and Exhibits' as item information.
When was this 8-K filing submitted to the SEC?
The filing was submitted on January 16, 2025, which is also the date of the earliest event reported.
Where is Omeros Corporation's principal executive office located?
Omeros Corporation's principal executive offices are located at 201 Elliott Avenue West, Seattle, WA 98119.
What industry does Omeros Corporation operate in?
Omeros Corporation operates in the Pharmaceutical Preparations industry, with Standard Industrial Classification code 2834.
Filing Stats: 461 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-01-16 09:25:11
Key Financial Figures
- $0.01 — ange on which registered Common stock, $0.01 par value per share OMER The Nasdaq
Filing Documents
- omer20250116c_8k.htm (8-K) — 25KB
- ex_766537.htm (EX-99.1) — 26KB
- ex_766537img001.jpg (GRAPHIC) — 3KB
- 0001437749-25-001245.txt ( ) — 192KB
- omer-20250116.xsd (EX-101.SCH) — 3KB
- omer-20250116_def.xml (EX-101.DEF) — 11KB
- omer-20250116_lab.xml (EX-101.LAB) — 15KB
- omer-20250116_pre.xml (EX-101.PRE) — 11KB
- omer20250116c_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On January 16, 2025, Omeros Corporation issued a press release announcing the results of statistical sensitivity analyses related to the previously reported primary endpoint analysis for narsoplimab, Omeros' first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated January 16, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OMEROS CORPORATION Date: January 16, 2025 By: /s/ Gregory A. Demopulos Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board of Directors